Active Biotech reports positive data in cancer trial

Sweden's Active Biotech has doubled the maximum tolerated dose of its experimental prostate therapy in a Phase Ib trial. Researchers increased dosage to 1 mg a day, which can be used in an upcoming mid-stage trial for the drug later this year. Active's stock price was buoyed by the news.

"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Active Biotech CEO Sven Andréasson.

- see the release on the trial data

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.